Genmab (Otc) ((GMAB)), Biontech Se Sponsored Adr ((BNTX)), Biontech SE (($CC:BNTX.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Genmab, in collaboration with BioNTech SE, is conducting a clinical trial titled ‘First-In-Human, Open-Label, Dose Escalation Trial With Expansion Cohorts to Evaluate the Safety and Preliminary Efficacy of GEN1055 as Monotherapy and as Combination Therapy in Subjects With Malignant Solid Tumors.’ The study aims to assess the safety and preliminary efficacy of the antibody GEN1055, both alone and in combination with pembrolizumab, in treating malignant solid tumors. This trial is significant as it explores potential new treatment options for cancer patients.
The intervention being tested is GEN1055, administered intravenously, either as a monotherapy or in combination with pembrolizumab and standard chemotherapy. GEN1055 is designed to target and treat malignant solid tumors, potentially offering a new therapeutic avenue for patients.
The study is interventional, with a sequential intervention model and no masking, focusing primarily on treatment. It consists of two parts: a dose escalation phase to determine safe dosage levels and an expansion phase to evaluate the selected doses’ safety and efficacy in specific tumor types.
The trial began on May 14, 2024, with its primary completion and estimated overall completion dates yet to be announced. The latest update was submitted on August 4, 2025. These dates are crucial for tracking the study’s progress and potential market impact.
This clinical trial update could influence Genmab’s and BioNTech’s stock performance, as positive results may boost investor confidence and market value. The study’s progress is also significant in the competitive oncology market, where innovative treatments are highly sought after.
The study is ongoing, with further details available on the ClinicalTrials portal.